Multimodale Therapie des Ösophaguskarzinoms

Das Ösophaguskarzinom ist eine lebensbedrohliche Erkrankung. Trotz interdisziplinärer Therapiestrategien liegt die 5-Jahres-Überlebensrate unter 50%. Dieser Artikel gibt einen Überblick über die Vor- und Nachteile der aktuell in Europa praktizierten multimodalen Therapie.

Schlüsselwörter

Adenokarzinom des Ösophagus - Plattenepithelkarzinom des Ösophagus - AEG - Therapiealgorithmus

• Literatur

• 1 Gupta B, Kumar N. Worldwide incidence, mortality and time trends for cancer of the oesophagus. Eur J Cancer Prev 2017; 26: 107-118
• 2 Onkopedia.com. Leitlinie Ösophaguskarzinom; 2018. Im Internet (Stand: 04.12.2020): https://www.onkopedia.com/de/onkopedia/guidelines/oesophaguskarzinom/@@guideline/html/index.html
• 3 Krebs in Deutschland für 2013/2014. 11. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., Hrsg. Berlin: 2017. Im Internet (Stand: 04.12.2020): https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2017/krebs_in_deutschland_2017.pdf?__blob=publicationFile
• 4 Lordick F, Mariette C, Haustermans K. et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (Suppl. 05) v50-v57
• 5 Siewert JR, Hölscher AH, Becker K. et al. [Cardia cancer: attempt at a therapeutically relevant classification]. Chirurg 1987; 58: 25-32
• 6 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus, Langversion 2.0; 2018. AWMF Registernummer: 021/023OL. Im Internet (Stand: 04.12.2020): https://www.leitlinienprogramm-onkologie.de/leitlinien/oesophaguskarzinom/
• 7 Wittekind C. [2010 TNM system: on the 7th edition of TNM classification of malignant tumors]. Pathologe 2010; 31: 331-332
• 8 Pech O, May A, Manner H. et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014; 146: 652-660.e1
• 9 Shapiro J, van Lanschot JJB, Hulshof MCCM. et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015; 16: 1090-1098
• 10 Wang K, Ren Y, Ma Z. et al. Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) as preoperative and postoperative chemotherapy compared with surgery followed by chemotherapy for patients with locally advanced gastric cancer: a propensity score-based analysis. Cancer Manag Res 2019; 11: 3009-3020
• 11 Lorenzen S, Biederstädt A, Ronellenfitsch U. et al. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction – a randomized phase III joint study of the AIO, ARO and DGAV. BMC Cancer 2020; 20: 886
• 12 Hoeppner J, Lordick F, Brunner T. et al. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer 2016; 16: 503
• 13 Low DE, Kuppusamy MK, Alderson D. et al. Benchmarking Complications Associated with Esophagectomy. Ann Surg 2019; 269: 291-298
• 14 Chen Y, Lu Y, Wang Y. et al. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone. Dis Esophagus 2014; 27: 134-140
• 15 Ma MW, Gao XS, Gu XB. et al. The role of definitive chemoradiotherapy versus surgery as initial treatments for potentially resectable esophageal carcinoma. World J Surg Oncol 2018; 16: 172 doi:10.1186/s12957-018-1470-y
• 16 Thuss-Patience P, Biebl M, Stromberger C. Multimodale Therapie des Ösophaguskarzinoms. Onkologe 2017; 23: 771-788
• 17 Grimminger PP, Fuchs HF. [Minimally invasive and robotic-assisted surgical management of upper gastrointestinal cancer]. Chirurg 2017; 88: 1017-1023
• 18 Grimminger PP, Tagkalos E, Hadzijusufovic E. et al. Change from Hybrid to Fully Minimally Invasive and Robotic Esophagectomy is Possible without Compromises. Thorac Cardiovasc Surg 2019; 67: 589-596
• 19 Akiyama H, Tsurumaru M, Udagawa H. et al. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994; 220: 364-372 discussion 372–373
• 20 Hölscher AH, Bollschweiler E, Beckurts KT. et al. [Extent of radical surgery in cardia carcinoma – esophagectomy or gastrectomy?]. Langenbecks Arch Chir Suppl Kongressbd 1996; 113: 169-172
• 21 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Magenkarzinom, Langversion 2.01 (Konsultationsfassung); 2019. AWMF Registernummer: 032/009OL. Im Internet (Stand: 4.12.2020): http://www.leitlinienprogramm-onkologie.de/leitlinien/magenkarzinom/
• 22 Bang YJ, Van Cutsem E, Feyereislova A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697
• 23 Cunningham D, Allum WH, Stenning SP. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20
• 24 Al-Batran SE, Homann N, Pauligk C. et al. FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393: 1948-1957 doi:10.1016/S0140-6736(18)32557-1